CN106074424A - A kind of Gliclazide sustained-release tablet and preparation method thereof - Google Patents
A kind of Gliclazide sustained-release tablet and preparation method thereof Download PDFInfo
- Publication number
- CN106074424A CN106074424A CN201610424064.3A CN201610424064A CN106074424A CN 106074424 A CN106074424 A CN 106074424A CN 201610424064 A CN201610424064 A CN 201610424064A CN 106074424 A CN106074424 A CN 106074424A
- Authority
- CN
- China
- Prior art keywords
- gliclazide
- release tablet
- sustained
- parts
- gliclazide sustained
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F27/00—Mixers with rotary stirring devices in fixed receptacles; Kneaders
- B01F27/05—Stirrers
- B01F27/11—Stirrers characterised by the configuration of the stirrers
- B01F27/112—Stirrers characterised by the configuration of the stirrers with arms, paddles, vanes or blades
- B01F27/1125—Stirrers characterised by the configuration of the stirrers with arms, paddles, vanes or blades with vanes or blades extending parallel or oblique to the stirrer axis
- B01F27/11251—Stirrers characterised by the configuration of the stirrers with arms, paddles, vanes or blades with vanes or blades extending parallel or oblique to the stirrer axis having holes in the surface
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F27/00—Mixers with rotary stirring devices in fixed receptacles; Kneaders
- B01F27/80—Mixers with rotary stirring devices in fixed receptacles; Kneaders with stirrers rotating about a substantially vertical axis
- B01F27/90—Mixers with rotary stirring devices in fixed receptacles; Kneaders with stirrers rotating about a substantially vertical axis with paddles or arms
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F35/00—Accessories for mixers; Auxiliary operations or auxiliary devices; Parts or details of general application
- B01F35/10—Maintenance of mixers
- B01F35/12—Maintenance of mixers using mechanical means
- B01F35/123—Maintenance of mixers using mechanical means using scrapers for cleaning mixers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mechanical Engineering (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of hypoglycemic Gliclazide sustained-release tablet, belong to Western medicine preparation technical field, it is made up of element sheet and coating, it is characterized in that based on slow releasing tablet total weight percent, described plain sheet consists of the following composition: gliclazide 30 70 parts, polyvinylpyrrolidone 10 30 parts, L alanine 8 10 parts, lubrication fluidizer 1 10 parts, alginic acid 5 15 parts and sweeting agent 1 20 parts；Described coating is to consist of the following composition based on 100 parts by slow releasing tablet gross weight: sodium carboxymethyl cellulose 0.5 3 parts, propylene glycol 0.5 5 parts, lubricates fluidizer 0.5 2 parts, uses specific Particle mixer to mix, and the tablet slow release of the present invention is steady.
Description
Technical field
The invention belongs to Western medicine preparation technical field, particularly to a kind of hypoglycemic Gliclazide sustained-release tablet.
Background technology
The gliclazide alone diet control of sequela that is mainly used in growing up is invalid, and without the sugar light, medium-sized of Ketosis-prone
Urine disease.Diabetes patient's retinopathy and metabolism, the disorder of vascular function can also be improved.Can close with biguanides oral hypoglycemic
For alone out of contior patient.Must will be regularly spaced medicine time, guarantee blood drug level maintaining treatment
, there is clothes for patients inconvenience in level, easily forgets clothes, misses, the shortcomings such as blood concentration fluctuation is big.
Summary of the invention
In order to overcome the deficiencies in the prior art, adjuvant screening, process optimization and equipment are changed by the present invention by lot of experiments
Enter, it is provided that a kind of Gliclazide sustained-release tablet.This tablet slow release, gastrointestinal side-effect are little, and preparation technology is simple.
The object of the present invention is achieved like this:
A kind of Gliclazide sustained-release tablet, is made up of element sheet and coating, based on slow releasing tablet total weight percent, and described plain sheet
Consist of the following composition: gliclazide 30-70 part, ALANINE 8-10 part, polyvinylpyrrolidone 10-30 part, lubricate fluidizer
Agent 1-10 part, alginic acid 5-15 part and sweeting agent 1-20 part；Described coating is by following one-tenth based on 100 parts by slow releasing tablet gross weight
It is grouped into: sodium carboxymethyl cellulose 0.5-3 part, propylene glycol 0.5-5 part, lubricates fluidizer 0.5-2 part.
Described Gliclazide sustained-release tablet, lubrication fluidizer one in magnesium stearate, silicon dioxide, the Pulvis Talci or
Multiple.
Described Gliclazide sustained-release tablet, sweeting agent selected from lactose, sucrose, glucose, xylitol, sorbitol, mannitol,
One or more in steviosin, saccharin sodium, aspartame.
Described Gliclazide sustained-release tablet, the plain slice prescription of Gliclazide sustained-release tablet is as follows: gliclazide 500mg, L-third
Propylhomoserin 90mg, polyvinylpyrrolidone 200mg, magnesium stearate 50mg, alginic acid 100mg, lactose 200mg；Gliclazide delayed-release
The coated formula of sheet is as follows: sodium carboxymethyl cellulose 10.5mg, propylene glycol 20mg, Pulvis Talci 9.5mg.
Described a kind of Gliclazide sustained-release tablet, the plain slice prescription of Gliclazide sustained-release tablet is as follows: gliclazide 500mg,
ALANINE 80mg, PVPK30 0mg, magnesium stearate 20mg, alginic acid 50mg, lactose 100mg；Gliclazide delays
The coated formula releasing sheet is as follows: sodium carboxymethyl cellulose 9.5mg, propylene glycol 19mg, Pulvis Talci 15mg.
Described a kind of Gliclazide sustained-release tablet, preparation method comprises the following steps: that (1) is by part polyethylene pyrrolidine
Ketone is dissolved in ethanol solution, is prepared as alcoholic solution；(2) gliclazide after sieving, remaining polyvinylpyrrolidone, L-
Alanine, alginic acid, sweeting agent are placed in Particle mixer and are sufficiently mixed, and add the alcoholic solution of above-mentioned polyvinylpyrrolidone,
It is sufficiently mixed, prepares soft material；(3) above-mentioned soft material being added lubrication fluidizer after drying, obtain mixed powder, mixed powder all adds
Enter Mixers with Multi-direction Movement, use swinging lozenge machine tabletting, prepare element sheet；(4) preparation of coating solution: will lubrication fluidizer mistake
Mix after sieve, add in the ethanol solution containing sodium carboxymethyl cellulose and propylene glycol, follow with colloid mill again after stirring by hand
Ring grinds, and prepares coating solution；(5) element sheet is joined in atresia coating pan, regulate intake, after element sheet preheating, in addition
State coating solution to be coated；(6) by prepared slow releasing tablet packaging.
Described Gliclazide sustained-release tablet, Particle mixer in preparation method, including mixing drum, mixing cover, actuating device
And mixing component, described mixing cover threadeds with described mixing drum, and described mixing component includes stirring axostylus axostyle and being connected to institute
Stating the stirring paddle that stirring axostylus axostyle is connected, described actuating device is connected with described stirring axostylus axostyle, it is characterised in that: stir described
Mix oar and be provided with circular hole, the sidewall of described circular hole is provided with regulating tank, in described regulating tank, be provided with adjustable plate, at described tune
It is provided with the little cylinder of regulation between joint plate and described regulating tank, between the inwall of described adjustable plate and described regulating tank, is provided with sealing
Circle, described adjustable plate moves the diameter adjustment realized circular hole under the effect of the little cylinder of described regulation in circular hole, described
The side of stirring paddle is provided with bar-shaped trough, is provided with screw mandrel in described bar-shaped trough, is provided with and described screw mandrel in described stirring paddle
The clockwise and anticlockwise motor being connected, is provided with scraper plate in described bar-shaped trough, and described scraper plate is movably arranged on described silk by movable block
On bar.
Described Gliclazide sustained-release tablet, in preparation method, the opening part of bar-shaped trough described in Particle mixer is provided with flexible
Type catch, described concertina type catch is connected between the sidewall of bar-shaped trough and scraper plate.
Described Gliclazide sustained-release tablet, concertina type catch described in Particle mixer and described bar-shaped trough in preparation method
Between be provided with seal block.
Described Gliclazide sustained-release tablet, in preparation method, scraper plate described in Particle mixer is flake plate body.
Compared with prior art, the Gliclazide sustained-release tablet that the present invention relates to has a most useful technique effect:
(1) release is steadily.(2) preparation technology is simple.The Gliclazide sustained-release tablet of present invention screening is suitable for the big life of industrialization
Produce.
Accompanying drawing explanation
Fig. 1 is the structural representation of Particle mixer
Detailed description of the invention
The foregoing of the present invention is described in further detail by form more by the following examples, but should this not managed
The scope for the above-mentioned theme of the present invention that solves is only limitted to Examples below, and all technology realized based on foregoing of the present invention all belong to
In the scope of the present invention.
Embodiment 1
The plain slice prescription weighing Gliclazide sustained-release tablet is as follows: gliclazide 500mg, ALANINE 90mg, polyethylene pyrrole
Pyrrolidone 200mg, magnesium stearate 50mg, alginic acid 100mg, lactose 200mg；The coated formula of Gliclazide sustained-release tablet is as follows:
Sodium carboxymethyl cellulose 10.5mg, propylene glycol 20mg, Pulvis Talci 9.5mg.
Preparation technology:
(1) 100mg polyvinylpyrrolidone is dissolved in ethanol solution, is prepared as alcoholic solution；(2) lattice after sieving
Lie Qite, remaining polyvinylpyrrolidone, ALANINE, alginic acid, lactose are placed in Particle mixer and are sufficiently mixed, and add
The alcoholic solution of above-mentioned polyvinylpyrrolidone, is sufficiently mixed, and prepares soft material；(3) above-mentioned soft material is added lubrication after drying to help
Stream agent, obtains mixed powder, and mixed powder all adds Mixers with Multi-direction Movement, uses swinging lozenge machine tabletting, prepares element sheet；
(4) preparation of coating solution: mix after being sieved by Pulvis Talci, adds in the ethanol solution containing sodium carboxymethyl cellulose and propylene glycol,
Use colloid mill circular grinding again after stirring by hand, prepare coating solution；(5) element sheet is joined in atresia coating pan, regulation
Good intake, after element sheet preheating, adds above-mentioned coating solution and is coated；(6) by prepared slow releasing tablet packaging.
Particle mixer is shown in Fig. 1, including mixing drum 1, mixing cover 2, actuating device 3 and mixing component 4, described mixing cover 2
Threadeding with described mixing drum 1, described mixing component 4 includes that stirring axostylus axostyle 41 is connected with being connected to described stirring axostylus axostyle 41
Stirring paddle 42, described actuating device 3 is connected with described stirring axostylus axostyle 41, is provided with circular hole 5, in institute on described stirring paddle 42
The sidewall stating circular hole 5 is provided with regulating tank 6, is provided with adjustable plate 7 in described regulating tank 6, in described adjustable plate and described regulation
It is provided with the little cylinder 8 of regulation between groove, by regulating the position of little cylinder control and regulation plate, thus the regulation of circular hole can be realized,
Regulating circular hole to maximum rating when stirring starts, now medical material can as much as possible be mixed by circular hole when stirring
Close, at the end of stirring is fast, circular hole regulated to minimum state, now major part medical material can be stirred oar side block and with
Rotate such that it is able to improve the amount that medical material is stirred, between described adjustable plate 7 and the inwall of described regulating tank 6, be provided with sealing ring
9, have sealing ring can prevent medical material from entering in regulating tank, described adjustable plate 7 under the effect of the little cylinder of described regulation 8 in circular hole
The mobile diameter adjustment realized circular hole 5, is provided with bar-shaped trough 10, on the side of described stirring paddle 42 in described bar-shaped trough 10
It is provided with screw mandrel 11, in described stirring paddle 42, is provided with the clockwise and anticlockwise motor 12 being connected with described screw mandrel 11, at described bar-shaped trough
Inside being provided with scraper plate 13, described scraper plate 13 is movably arranged on described screw mandrel 11 by movable block 14.Can also pass through when stirring
Clockwise and anticlockwise motor control scraper plate moves the medical material that will be attached to stirring paddle side and is scraped, thus can prevent because being attached to stirring paddle
Side and affect the deficiency of mixing.
Opening part at described bar-shaped trough 10 is provided with concertina type catch 15, and described concertina type catch is connected to the side of bar-shaped trough
Between wall and scraper plate.When scraper plate moves in bar-shaped trough, the concertina type catch of one end is compressed by band, the concertina type gear of the other end
Sheet stretches, thus can prevent medical material from entering in bar-shaped trough, it is ensured that the stability that screw mandrel runs.
It is provided with seal block 16 between described concertina type catch and described bar-shaped trough.
Described scraper plate is flake plate body.
Embodiment 2
The plain slice prescription weighing Gliclazide sustained-release tablet is as follows: gliclazide 500mg, ALANINE 80mg, polyethylene pyrrole
Pyrrolidone 300mg, magnesium stearate 20mg, alginic acid 50mg, lactose 100mg；The coated formula of Gliclazide sustained-release tablet is as follows: carboxylic
Sodium carboxymethylcellulose pyce 9.5mg, propylene glycol 19mg, Pulvis Talci 15mg.
Preparation technology is ibid.
The release research of embodiment 3 Gliclazide sustained-release tablet
Tablet (specification 50mg) dative Lie Qi special envoy Example 1 and Example 2 of the present invention prepared stirs by plain particles
Mixing machine, tablet prepared by direct compression contrasts.
Dissolution test method: Example 1 and tablet (specification 50mg) the dative Lie Qi special envoy of embodiment 2 preparation respectively
Using plain particles blender, tablet (specification 50mg) prepared by direct compression, according to drug release determination method (Chinese Pharmacopoeia version in 2010
Two annex Ⅹ D the first methods), Chinese Pharmacopoeia version annex in 2010,75 turns/min of blue laws, to go the fresh water 1000ml of air to be
This product release solvent.Ultraviolet spectrophotometry is selected to utilize absorption coefficient method to measure releasing of Gliclazide sustained-release tablet at 233nm
Degree of putting.
Dissolution of sustained-release tablets measurement result prepared by each embodiment of table 1
| Sample source | 1h (%) | 3h (%) | 6h (%) | 9h (%) | 12h (%) | 24h (%) |
| Embodiment 1 | 21.4 | 53.8 | 71.4 | 88.2 | 95.6 | 102.3 |
| Embodiment 2 | 17.8 | 31.4 | 62.8 | 74.6 | 94.6 | 99.8 |
| Comparative example 1 | 65.6 | 96.4 | 99.8 | 101.3 | 99.9 | 99.4 |
According to the result of the test of table 1, Gliclazide sustained-release tablet release prepared by embodiment of the present invention 1-2 is steadily；Right
Plain particles blender is used to mix gliclazide than embodiment 1, owing in the granule of preparation, gliclazide is not filled by adjuvant
Subpackage is wrapped up in, therefore discharges too fast.
Claims (10)
1. a Gliclazide sustained-release tablet, is made up of element sheet and coating, it is characterised in that based on slow releasing tablet total weight percent, institute
The plain sheet stated consists of the following composition: gliclazide 30-70 part, ALANINE 8-10 part, polyvinylpyrrolidone 10-30 part,
Lubrication fluidizer 1-10 part, alginic acid 5-15 part and sweeting agent 1-20 part；Described coating is based on 100 parts by slow releasing tablet gross weight
Consist of the following composition: sodium carboxymethyl cellulose 0.5-3 part, propylene glycol 0.5-5 part, lubricate fluidizer 0.5-2 part.
2. Gliclazide sustained-release tablet as claimed in claim 1 a kind of, it is characterised in that lubrication fluidizer selected from magnesium stearate, two
One or more in silicon oxide, Pulvis Talci.
3. a kind of Gliclazide sustained-release tablet as claimed in claim 1, it is characterised in that sweeting agent is selected from lactose, sucrose, Fructus Vitis viniferae
One or more in sugar, xylitol, sorbitol, mannitol, steviosin, saccharin sodium, aspartame.
4. a kind of Gliclazide sustained-release tablet as claimed in claim 1, it is characterised in that the plain slice prescription of Gliclazide sustained-release tablet
As follows: gliclazide 500mg, ALANINE 90mg, polyvinylpyrrolidone 200mg, magnesium stearate 50mg, alginic acid 100mg,
Lactose 200mg；The coated formula of Gliclazide sustained-release tablet is as follows: sodium carboxymethyl cellulose 10.5mg, propylene glycol 20mg, Pulvis Talci
9.5mg。
5. a kind of Gliclazide sustained-release tablet as claimed in claim 1, it is characterised in that the plain slice prescription of Gliclazide sustained-release tablet
As follows: gliclazide 500mg, ALANINE 80mg, PVPK30 0mg, magnesium stearate 20mg, alginic acid 50mg,
Lactose 100mg；The coated formula of Gliclazide sustained-release tablet is as follows: sodium carboxymethyl cellulose 9.5mg, propylene glycol 19mg, Pulvis Talci
15mg。
6. a kind of Gliclazide sustained-release tablet as claimed in claim 1, it is characterised in that preparation method comprises the following steps:
(1) part polyethylene ketopyrrolidine is dissolved in ethanol solution, is prepared as alcoholic solution；(2) gliclazide after sieving, surplus
Under polyvinylpyrrolidone, ALANINE, alginic acid, sweeting agent be placed in Particle mixer and be sufficiently mixed, add above-mentioned poly-
The alcoholic solution of vinylpyrrolidone, is sufficiently mixed, and prepares soft material；(3) above-mentioned soft material is added lubrication fluidizer after drying,
To mixed powder, mixed powder all adds Mixers with Multi-direction Movement, uses swinging lozenge machine tabletting, prepares element sheet；(4) coating solution
Preparation: mix after lubrication fluidizer is sieved, add in the ethanol solution containing sodium carboxymethyl cellulose and propylene glycol, stir by hand
Use colloid mill circular grinding again after mixing uniformly, prepare coating solution；(5) element sheet is joined in atresia coating pan, regulate air intake
Amount, after element sheet preheating, adds above-mentioned coating solution and is coated；(6) by prepared slow releasing tablet packaging.
7. a kind of Gliclazide sustained-release tablet as claimed in claim 6, it is characterised in that Particle mixer in preparation method, including
Mixing drum, mixing cover, actuating device and mixing component, described mixing cover threadeds with described mixing drum, described mixing component
Including stirring axostylus axostyle and being connected to the stirring paddle that described stirring axostylus axostyle is connected, described actuating device is connected with described stirring axostylus axostyle
Connect, it is characterised in that: on described stirring paddle, it is provided with circular hole, the sidewall of described circular hole is provided with regulating tank, in described regulation
It is provided with adjustable plate in groove, between described adjustable plate and described regulating tank, is provided with the little cylinder of regulation, at described adjustable plate with described
Being provided with sealing ring between the inwall of regulating tank, described adjustable plate is mobile in circular hole under the effect of the little cylinder of described regulation to be realized
Diameter adjustment to circular hole, is provided with bar-shaped trough on the side of described stirring paddle, is provided with screw mandrel in described bar-shaped trough, described
Being provided with the clockwise and anticlockwise motor being connected with described screw mandrel in stirring paddle, be provided with scraper plate in described bar-shaped trough, described scraper plate passes through
Movable block is movably arranged on described screw mandrel.
8. a kind of Gliclazide sustained-release tablet as claimed in claim 7, it is characterised in that institute in Particle mixer in preparation method
The opening part stating bar-shaped trough is provided with concertina type catch, and described concertina type catch is connected between the sidewall of bar-shaped trough and scraper plate.
9. a kind of Gliclazide sustained-release tablet as claimed in claim 7, it is characterised in that institute in Particle mixer in preparation method
State and be provided with seal block between concertina type catch and described bar-shaped trough.
10. a kind of Gliclazide sustained-release tablet as claimed in claim 7, it is characterised in that institute in Particle mixer in preparation method
State scraper plate for flake plate body.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610424064.3A CN106074424A (en) | 2016-06-14 | 2016-06-14 | A kind of Gliclazide sustained-release tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610424064.3A CN106074424A (en) | 2016-06-14 | 2016-06-14 | A kind of Gliclazide sustained-release tablet and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106074424A true CN106074424A (en) | 2016-11-09 |
Family
ID=57846482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610424064.3A Pending CN106074424A (en) | 2016-06-14 | 2016-06-14 | A kind of Gliclazide sustained-release tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106074424A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106860413A (en) * | 2017-02-15 | 2017-06-20 | 青岛市中心医院 | To oesophagus without pair work and antineoplastic Gliclazide sustained-release tablet and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101647785A (en) * | 2008-08-15 | 2010-02-17 | 北京科信必成医药科技发展有限公司 | Gliclazide sustained-release tablet and preparation method thereof |
| CN102988323A (en) * | 2012-10-08 | 2013-03-27 | 李正梅 | Preparation method of aniracetam sustained-release tablet |
-
2016
- 2016-06-14 CN CN201610424064.3A patent/CN106074424A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101647785A (en) * | 2008-08-15 | 2010-02-17 | 北京科信必成医药科技发展有限公司 | Gliclazide sustained-release tablet and preparation method thereof |
| CN102988323A (en) * | 2012-10-08 | 2013-03-27 | 李正梅 | Preparation method of aniracetam sustained-release tablet |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106860413A (en) * | 2017-02-15 | 2017-06-20 | 青岛市中心医院 | To oesophagus without pair work and antineoplastic Gliclazide sustained-release tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2423113C2 (en) | Solid preparative forms of ospemifene | |
| CN1871018A (en) | Pharmaceutical formulation comprising lanthanum compounds | |
| CN1212626A (en) | Tablets containing 'beta'-lactam antibiotic and process for producing the same | |
| CN103479592B (en) | Metformin hydrochloride sustained release tablets and preparation method thereof | |
| WO2015051747A1 (en) | Pramipexole extended release tablet and preparation method and use thereof | |
| CN106074424A (en) | A kind of Gliclazide sustained-release tablet and preparation method thereof | |
| CN104825408A (en) | Azithromycin dispersible tablet and preparation method and use thereof | |
| JP2019516706A (en) | Novel crystalline form of dapagliflozin and method for producing and use thereof | |
| CN103251593B (en) | Repaglinide/metformin composition | |
| CN103251594B (en) | Repaglinide/metformin combo tablet | |
| CN111557920A (en) | Lipoic acid-containing tablet and preparation method thereof | |
| CN104739835A (en) | Novel pharmaceutical composition for treating diabetes | |
| CN114767648B (en) | Exemestane film coated tablet and preparation method thereof | |
| CN101653580B (en) | Medicament for curing stomach illness and preparation thereof | |
| CN106074426A (en) | A kind of Theo-Dur treating bronchial asthma and preparation method thereof | |
| CN106074425A (en) | A kind of hypoglycemic diabecron sustained-release tablet and preparation method thereof | |
| CN103251569A (en) | Capecitabine tablet composition and preparation method thereof | |
| CN113274365B (en) | Ramelteon quick-release slow-release double-release preparation and preparation method thereof | |
| CN107050116B (en) | Traditional Chinese medicine pill for treating diabetic nephropathy and preparation method and application thereof | |
| CN103371981A (en) | Compound repaglinide-metformin hydrochloride solid quick-release preparation and preparation method and application thereof | |
| CN103505427A (en) | Agomelatine tablet | |
| CN111728946A (en) | Acarbose tablet composition and preparation method thereof | |
| CN105106144A (en) | Cinacalcet hydrochloride solid dispersion tablet and preparation technology thereof | |
| CN105878203A (en) | Lansoprazole enteric-coated tablet for treating gastric ulcer and preparation method thereof | |
| CN106310229A (en) | Macimorelin film coated tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161109 |